Cadence Neuroscience develops a neuromodulation therapy that uses chronic subthreshold cortical stimulation to modulate EEG biomarkers and reduce or eliminate seizures. The therapy is based on research from a Mayo Clinic neurology and neurosurgery team led by Gregory Worrell, M.D., Ph.D. Cadence is clinical‑stage and intends to use the new funding to complete pivotal clinical studies and pursue FDA clearance. The company is led by CEO Kent Leyde and was founded in 2017. It is based in Redmond, WA and focuses on treating both pediatric and adult patients with focal drug‑resistant epilepsy. Cadence recently closed a Series B financing to advance its clinical program. Cadence Neuroscience is an early-stage medical device company founded in 2017 by Kent Leyde and based in Redmond, Wash. Its core technology was developed at Mayo Clinic’s Rochester campus and is currently under clinical evaluation. The company is developing a therapy that uses chronic subthreshold cortical stimulation to modulate EEG biomarkers associated with epilepsy to reduce or eliminate seizures; the approach was developed by a Mayo Clinic neurology and neurosurgery team led by Gregory Worrell, Mathew Stead, Brian Lundstrom, Ben Brinkmann and Jamie VanGompel. Cadence plans to use new funding to further develop the technology, conduct clinical studies, and pursue FDA approval. The company focuses on therapies for epilepsy and other neurological disorders and remains in early clinical and development stages.

Total raised

$41M

Funding rounds

2

Latest round

Series B

Latest activity

May 2023